BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 20071294)

  • 1. Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study.
    Curigliano G; Spitaleri G; Magni E; Lorizzo K; De Cobelli O; Locatelli M; Fumagalli L; Adamoli L; Cossu Rocca M; Verri E; De Pas T; Jereczek-Fossa B; Martinelli G; Goldhirsch A; Nolè F
    J Chemother; 2009 Dec; 21(6):687-92. PubMed ID: 20071294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
    Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
    J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
    Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
    Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
    J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testicular germ cell tumors in adolescents - results of the protocol MAHO 98 and the identification of good risk patients.
    Göbel U; Calaminus G; Haas R; Teske C; Schönberger S; Schneider DT; Leuschner I; Harms D
    Klin Padiatr; 2014 Nov; 226(6-7):316-22. PubMed ID: 25431864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Modified retroperitoneal lymphadenectomy in non-seminomatous stage I, IIa and IIb testicular tumors].
    Sparwasser C; Treiber U; Beckert R; Pust RA
    Urologe A; 1995 Nov; 34(6):444-8. PubMed ID: 8848854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group.
    Bamias A; Aravantinos G; Kastriotis I; Alivizatos G; Anastasiou I; Christodoulou C; Gyftaki R; Kalofonos HP; Dimopoulos MA
    Urol Oncol; 2011; 29(2):189-93. PubMed ID: 19362863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological outcome of delayed orchidectomy after primary chemotherapy for metastatic germ cell tumour of the testis.
    Ramani VA; Grey BR; Addla SK; Dunham MP; Sangar VK; Clarke NW
    Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):247-52. PubMed ID: 18093814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
    Cushing B; Giller R; Cullen JW; Marina NM; Lauer SJ; Olson TA; Rogers PC; Colombani P; Rescorla F; Billmire DF; Vinocur CD; Hawkins EP; Davis MM; Perlman EJ; London WB; Castleberry RP; ;
    J Clin Oncol; 2004 Jul; 22(13):2691-700. PubMed ID: 15226336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
    Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study.
    Wozniak AJ; Samson MK; Shah NT; Crawford ED; Ford CD; Altman SJ; Stephens RL; Natale RB; Bouroncle BA; Blumenstein BA
    J Clin Oncol; 1991 Jan; 9(1):70-6. PubMed ID: 1702148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
    Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
    Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.
    Bosl GJ; Geller NL; Bajorin D; Leitner SP; Yagoda A; Golbey RB; Scher H; Vogelzang NJ; Auman J; Carey R
    J Clin Oncol; 1988 Aug; 6(8):1231-8. PubMed ID: 2457657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer.
    Pizzocaro G; Piva L; Salvioni R; Zanoni F; Milani A
    Cancer; 1985 Nov; 56(10):2411-5. PubMed ID: 2412683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
    Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
    Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [BEP (bleomycin, etoposide, cisplatin) therapy for testicular tumors].
    Mori Y; Shima H; Ihara H; Yabumoto H; Iwasaki A; Yoshioka M; Ikoma F
    Hinyokika Kiyo; 1992 Oct; 38(10):1139-42. PubMed ID: 1282774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the number of cycles of cisplatin based chemotherapy have any effect on renal function in patients with testicular germ cell tumor?
    Suer E; Mermerkaya M; Gülpınar Ö; Afandiyev F; Baltacı S; Türkölmez K; Bedük Y
    J Urol; 2013 Dec; 190(6):2081-5. PubMed ID: 23764076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin.
    Brada M; Horwich A; Peckham MJ
    Cancer Treat Rep; 1987 Jun; 71(6):655-6. PubMed ID: 2438041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
    Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.